Results 1 to 10 of about 69,085 (277)
Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells. [PDF]
, 2014 BACKGROUND: The importance of the genetic background of cancer cells for the individual susceptibility to cancer treatments is increasingly apparent.
Arozarena, Imanol +5 more
core +2 more sources
Acta Medica Bulgarica, 2021 Introduction: Thyroid carcinoma is the most common endocrine cancer. Some somatic mutations in genes (BRAF, NRAS and TERT) involved in key signaling pathways and genome stability have been recently identified to play an important role in its development.
Vidinov K. +8 more
doaj +1 more source
Regulatory quality and performance in EU network industries: Evidence on telecommunications, gas and electricity [PDF]
, 2009 This article provides empirical evidence on ex ante and ex post indicators of regulatory quality and the relationship between those indicators and market performance in liberalised EU-15 network industries. It finds a low level of regulatory independence
Frankfurter +9 more
core +1 more source
In vivo E2F reporting reveals efficacious schedules of MEK1/2–CDK4/6 targeting and mTOR–s6 resistance mechanisms [PDF]
, 2018 Targeting cyclin-dependent kinases 4/6 (CDK4/6) represents a therapeutic option in combination with BRAF inhibitor and/or MEK inhibitor (MEKi) in melanoma; however, continuous dosing elicits toxicities in patients. Using quantitative and temporal in vivo
Aplin, Andrew E. +14 more
core +1 more source
Türk Patoloji Dergisi, 2023 Objective: Primary anorectal melanomas (AMs) are uncommon neoplasms with aggressive behavior. Molecular profile and clinicopathologic features of AMs are still not well established.
Orhun Cig TASKIN +6 more
doaj +1 more source
iScience, 2022 Summary: NRas is a key mediator of the mitogenic pathway in normal cells and in cancer cells. Its dynamics and nanoscale organization at the plasma membrane (PM) facilitate its signaling.
Oren Yakovian +5 more
doaj +1 more source
PROGNOSTIC SIGNIFICANCE OF NRAS GENE MUTATIONS IN CHILDREN WITH ACUTE MYELOGENOUS LEUKEMIA
Mediterranean Journal of Hematology and Infectious Diseases, 2011 Background: NRAS mutations are the most commonly detected molecular abnormalities in hematologic malignancies, especially in those of myeloid origin.
Rabab Aly +2 more
doaj +3 more sources
Radiology and Oncology, 2019 Colorectal cancer is a successful model of genetic biomarker development in oncology. Currently, several predictive or prognostic genetic alterations have been identified and are used in clinical practice.
Afrăsânie Vlad-Adrian +7 more
doaj +1 more source
NRAS mutant melanoma - undrugable?
Oncotarget, 2013 Mutations in the three rat sarcoma (RAS) family members NRAS (neuroblastoma-RAS), HRAS (Harvey-RAS) and KRAS (Kirsten-RAS) are found in one third of human cancers. Among the first oncogenes discovered in cutaneous melanoma was NRAS, which is mutant in up to 20% of tumors causing aberrant signaling in several downstream cascades. Despite, being a highly
Christian, Posch, Susana, Ortiz-Urda
openaire +3 more sources
EGFR inhibitor as second-line therapy in a patient with mutant RAS metastatic colorectal cancer: circulating tumor DNA to personalize treatment [PDF]
, 2018 A 47-year-old male patient presented in March 2016 to our unit with a palpable painless left supraclavicular mass. A whole-body contrastenhanced computed tomography (CT) scan revealed a left supraclavicular lymphadenopathy, transverse colon thickening ...
Cortesi, Enrico +3 more
core +1 more source